BiotechTube
Winniedel Oncology

Winniedel Oncology

Cambridge, United States· Est.
winniedeloncology.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Winniedel Oncology is a niche, US-based CRO that has carved out a unique position by focusing solely on the study start-up phase for early-phase (First-in-Human to Phase 2b) oncology trials. The company leverages a proprietary global network of over 250 cancer centers and a relationship-driven model to achieve faster site activation, claiming it can complete SSU in 90 days or less while offering significant cost savings compared to traditional CROs. Led by a seasoned medical oncologist, Winniedel offers a blend of strategic clinical development guidance and hands-on operational execution, positioning itself as a critical partner for emerging biotech companies with novel oncology assets.

Oncology

Technology Platform

Proprietary Global Oncology Site Universe (GOSU), a curated network of 250+ clinical trial sites across 28 countries, combined with optimized study start-up (SSU) processes and relationship-driven site procurement models.

Opportunities

The growing number of emerging biotech companies with novel oncology assets creates a strong demand for specialized, efficient operational support.
Increasing industry focus on reducing clinical trial timelines and costs provides a tailwind for niche service providers that can demonstrably accelerate study start-up.

Risk Factors

High dependence on a niche service (oncology SSU) and potentially on key individual expertise creates concentration risk.
Intense competition from large, full-service CROs and other niche consultants threatens market share.
The business model may face scalability challenges while maintaining its promised personalized service.

Competitive Landscape

Winniedel competes against large, global full-service CROs (e.g., IQVIA, PPD, ICON) that offer SSU services as part of broader packages, and against other specialized oncology consultancies and boutique CROs. Its differentiation is its exclusive focus on early-phase oncology SSU, its claimed speed (90-day goal), and its curated global site network.

More companies in Oncology (General) →More companies in United States →